BioMedTracker is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.


Report Library

All Reports
Datamonitor Healthcare CV&Met: Chemotherapy-Induced Anemia (CIA) Market Spotlight

November 15, 2019

Anemia is the most common hematological complication in cancer patients, and refers to a reduced oxygen-carrying capacity in the blood. Cancer-related anemia can occur as a result of the cancer itself or chemotherapy treatment (known as chemotherapy-induced anemia [CIA]). CIA arises due to the myelotoxicity of chemotherapy drugs, which impairs erythropoiesis in the bone marrow. It can also develop because of underlying co-morbidities such as loss of blood and lack of iron. CIA may delay or lower the patient’s response to treatment, as well as cause fatigue and reduce quality of life. The condition generally improves after the chemotherapy treatment cycle ends; however, nephrotoxic effects of some platinum-based drugs can cause persistent anemia by decreasing the production of erythropoietin (EPO) by the kidney.

This Datamonitor Healthcare report contains a Market Spotlight module.
Indications Covered: Anemia Due to Oncology Treatment
Back to the top Back to the top